within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05C_IrrigatingSolutions.B05CA05_Taurolidine;

model Taurolidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.3333333333333332e-06,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.012,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.006,
    k12 = 6.388888888888888e-07,
    k21 = 6.388888888888888e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Taurolidine</td></tr><tr><td>ATC code:</td><td>B05CA05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Taurolidine is an antimicrobial agent derived from taurine, primarily used as an antimicrobial irrigating solution to prevent catheter-related bloodstream infections and as an adjunctive treatment in peritonitis and certain surgical procedures. It is not widely approved as a systemically administered drug and is used mostly for local/antimicrobial applications. Taurolidine is not broadly approved for systemic therapeutic use in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are for healthy adult volunteers following intravenous infusion of taurolidine.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B05CA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Taurolidine;
